The generic name for the medication Spravato is esketamine [1]. Esketamine is a non-competitive antagonist of NMDA receptors [2].
What is esketamine used for?
Esketamine is indicated for the treatment of treatment-resistant depression (TRD) in adults [2]. It is also used for depressive symptoms in adults with Major Depressive Disorder (MDD) with acute suicidal ideation or behavior [2].
How is esketamine administered?
Esketamine nasal spray is administered under the supervision of a healthcare provider in a certified medical office or clinic [3]. Patients are monitored for at least two hours after administration due to the risk of sedation and dissociation [3].
What are the potential side effects of esketamine?
Common side effects reported with esketamine include dissociation, dizziness, nausea, sedation, vertigo, and increased blood pressure [2]. Healthcare providers monitor patients for these effects.
When does the patent for esketamine expire?
DrugPatentWatch.com provides information on patent expirations for various drugs [4]. Specific patent expiration dates for esketamine can be found by searching their database. However, patent exclusivity periods can be extended or challenged through various legal and regulatory mechanisms.
Are there other medications similar to esketamine?
Esketamine is a derivative of ketamine, which also acts as an NMDA receptor antagonist and has been used off-label for depression. While other antidepressants target different neurotransmitter systems, esketamine's mechanism of action at NMDA receptors is distinct from many traditional antidepressants [5].
What is the mechanism of action for esketamine?
Esketamine is believed to work by rapidly increasing levels of the neurotransmitter glutamate in the brain [5]. This, in turn, may help to restore synaptic connections in certain brain circuits that are disrupted by chronic stress or depression [5].
What are the risks associated with esketamine treatment?
Beyond the side effects, there are risks associated with esketamine treatment, including the potential for abuse and dependence, as well as the risk of suicidal thoughts and behaviors [2]. Due to these risks, Spravato is available only through a Risk Evaluation and Mitigation Strategy (REMS) program [3].
What is the difference between esketamine and ketamine?
Esketamine is the S-enantiomer of ketamine. While both are NMDA receptor antagonists, esketamine is formulated as a nasal spray for specific indications and administration protocols, whereas ketamine has historically been administered intravenously or intramuscularly for anesthesia and is used off-label for depression [5].
How is esketamine regulated?
Esketamine, marketed as Spravato, was approved by the U.S. Food and Drug Administration (FDA) [3]. Its use is restricted to certified healthcare settings due to safety concerns, necessitating a REMS program [3].
What clinical data supports the use of esketamine?
Clinical trials have demonstrated that esketamine nasal spray, when used in conjunction with an oral antidepressant, can lead to rapid reductions in depressive symptoms in adults with TRD and those with MDD with acute suicidal ideation or behavior [2].
Sources:
[1] https://www.drugs.com/dictionary/esketamine.html
[2] https://www.janssen.com/spravato/about-spravato/mechanism-of-action-and-clinical-pharmacology
[3] https://www.spravato.com/
[4] https://drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697424/